Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy used in assisted reproductive technologies (ART), specifically for controlled ovarian stimulation. The protocol combines gonadotropins (FSH and LH, often administered as human menopausal gonadotropin or recombinant FSH) with cetrorelix, a GnRH antagonist. FSH and LH stimulate follicular growth and development, while cetrorelix prevents premature LH surges by blocking GnRH receptors on pituitary cells. This controlled approach allows for proper follicular maturation before triggering ovulation with human chorionic gonadotropin (hCG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on follicle stimulating hormone + luteinizing hormone + cetrorelix.